

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. -66. (Canceled)

67. (Currently Amended) An isolated, infectious, self-replicating, recombinant human parainfluenza virus type 2 (HPIV2) comprising a PIV major nucleocapsid (N) protein, a PIV nucleocapsid phosphoprotein (P), a PIV large polymerase protein (L), and a partial or complete, polyhexameric recombinant HPIV2 genome or antigenome having one or more attenuating mutation(s) selected from amino acid substitution(s) or deletion(s) at residues 948 and/or 1566 of the HPIV2 L polymerase.

68. - 72. (Canceled)

73. (Original) The recombinant HPIV2 of claim 67, wherein the recombinant HPIV2 genome or antigenome incorporates one or more recombinantly-introduced attenuating mutations.

74. (Original) The recombinant HPIV2 of claim 67, wherein the recombinant HPIV2 genome or antigenome incorporates one or more recombinantly-introduced attenuating mutations at one or more amino acid position(s) corresponding to an amino acid position of an attenuating mutation identified in a heterologous, mutant nonsegmented negative stranded RNA virus.

75. (Original) The recombinant HPIV2 of claim 74, wherein the polynucleotide molecule encoding the recombinant HPIV2 genome or antigenome incorporates one or more mutation(s) of HPIV3 JS *cp45*.

76 - 254. (Canceled)

255. (Currently Amended) An isolated polynucleotide comprising a partial or complete, polyhexameric recombinant human parainfluenza virus type 2 (HPIV2) genome or antigenome modified by one or more attenuating mutations that are recombinantly introduced into said HPIV2 genome or antigenome at any nucleotide used to encode residues 948 and/or 1566 of the HPIV2 L polymerase.

256. - 277. (Canceled)

278. (Currently Amended) An expression vector comprising an operably linked transcriptional promoter, a polynucleotide sequence comprising a partial or complete, polyhexameric recombinant human parainfluenza virus type 2 (HPIV2) genome or antigenome modified by one or more attenuating mutations that are recombinantly introduced into said HPIV2 genome or antigenome at any nucleotide used to encode residues 948 and/or 1566 of the HPIV2 L polymerase, and a transcriptional terminator.

279. - 294. (Canceled)